These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 16523360)
61. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169 [TBL] [Abstract][Full Text] [Related]
62. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. Doeden K; Ma Z; Narasimhan B; Swetter SM; Detmar M; Dadras SS J Cutan Pathol; 2009 Jul; 36(7):772-80. PubMed ID: 19032379 [TBL] [Abstract][Full Text] [Related]
63. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. Gimotty PA; Van Belle P; Elder DE; Murry T; Montone KT; Xu X; Hotz S; Raines S; Ming ME; Wahl P; Guerry D J Clin Oncol; 2005 Nov; 23(31):8048-56. PubMed ID: 16258103 [TBL] [Abstract][Full Text] [Related]
64. Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors). Murali R; Sharma RN; Thompson JF; Stretch JR; Lee CS; McCarthy SW; Scolyer RA Ann Surg Oncol; 2008 Jan; 15(1):302-9. PubMed ID: 18000712 [TBL] [Abstract][Full Text] [Related]
65. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Sondak VK; Taylor JM; Sabel MS; Wang Y; Lowe L; Grover AC; Chang AE; Yahanda AM; Moon J; Johnson TM Ann Surg Oncol; 2004 Mar; 11(3):247-58. PubMed ID: 14993019 [TBL] [Abstract][Full Text] [Related]
66. Idiosyncrasies of scalp melanoma. Rigual NR; Cheney RT; Iwenofu OH; Li Q; Loree TR; Popat SR; Merzianu M Laryngoscope; 2007 Aug; 117(8):1354-8. PubMed ID: 17592396 [TBL] [Abstract][Full Text] [Related]
67. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Shen J; Gilcrease MZ; Babiera GV; Ross MI; Meric-Bernstam F; Feig BW; Kuerer HM; Francis A; Ames FC; Hunt KK Cancer; 2007 Apr; 109(7):1255-63. PubMed ID: 17330229 [TBL] [Abstract][Full Text] [Related]
68. A scoring system to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a comparison with other scoring systems. Cho J; Han W; Lee JW; Ko E; Kang SY; Jung SY; Kim EK; Moon WK; Cho N; Park IA; Chung JK; Hwang KT; Kim SW; Noh DY Ann Surg Oncol; 2008 Aug; 15(8):2278-86. PubMed ID: 18528729 [TBL] [Abstract][Full Text] [Related]
69. Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma. Petitt M; Allison A; Shimoni T; Uchida T; Raimer S; Kelly B J Am Acad Dermatol; 2009 Nov; 61(5):819-28. PubMed ID: 19836642 [TBL] [Abstract][Full Text] [Related]
70. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy. Dalal KM; Patel A; Brady MS; Jaques DP; Coit DG Ann Surg Oncol; 2007 Jun; 14(6):1934-42. PubMed ID: 17406951 [TBL] [Abstract][Full Text] [Related]
71. Osteopontin as a molecular prognostic marker for melanoma. Rangel J; Nosrati M; Torabian S; Shaikh L; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M Cancer; 2008 Jan; 112(1):144-50. PubMed ID: 18023025 [TBL] [Abstract][Full Text] [Related]
72. Significance of multiple lymphatic basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. McHugh JB; Su L; Griffith KA; Schwartz JL; Wong SL; Cimmino V; Chang AE; Johnson TM; Sabel MS Ann Surg Oncol; 2006 Sep; 13(9):1216-23. PubMed ID: 16952026 [TBL] [Abstract][Full Text] [Related]
73. Outcome of patients with melanoma and histologically negative sentinel lymph nodes: one institution's experience. De Giorgi V; Leporatti G; Massi D; Lo Russo G; Sestini S; Dini M; Lotti T Oncology; 2007; 73(5-6):401-6. PubMed ID: 18515980 [TBL] [Abstract][Full Text] [Related]
74. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution. Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518 [TBL] [Abstract][Full Text] [Related]
75. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma. Caracò C; Marone U; Celentano E; Botti G; Mozzillo N Ann Surg Oncol; 2007 Sep; 14(9):2662-7. PubMed ID: 17597345 [TBL] [Abstract][Full Text] [Related]
76. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. Katz A; Smith BL; Golshan M; Niemierko A; Kobayashi W; Raad RA; Kelada A; Rizk L; Wong JS; Bellon JR; Gadd M; Specht M; Taghian AG J Clin Oncol; 2008 May; 26(13):2093-8. PubMed ID: 18445838 [TBL] [Abstract][Full Text] [Related]
77. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Kretschmer L; Beckmann I; Thoms KM; Mitteldorf C; Bertsch HP; Neumann C Ann Surg Oncol; 2006 Aug; 13(8):1105-12. PubMed ID: 16865591 [TBL] [Abstract][Full Text] [Related]
78. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Cox C; White L; Allred N; Meyers M; Dickson D; Dupont E; Cantor A; Ly Q; Dessureault S; King J; Nicosia S; Vrcel V; Diaz N Ann Surg Oncol; 2006 May; 13(5):708-11. PubMed ID: 16538416 [TBL] [Abstract][Full Text] [Related]
79. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. Reed J; Rosman M; Verbanac KM; Mannie A; Cheng Z; Tafra L J Am Coll Surg; 2009 Mar; 208(3):333-40. PubMed ID: 19317993 [TBL] [Abstract][Full Text] [Related]
80. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]